Anna L. Goodman - Concepedia

Author

Anna L. Goodman

Also Known As

A Goodman, A L Goodman, A. Goodman, A. L. GOODMAN, A. L. Goodman, A.L. Goodman, ANNA GOODMAN, Andrew Smith, Anna L. Goodman, Anna Goodman

175

Publications

16K

Citations

H-Index

Concepts

All Affiliations

University of Oxford University College London Jenner Institute Guy's and St Thomas' NHS Foundation Trust Imperial College London

About

Anna L. Goodman is an author at University of Oxford specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	19	3.6K
2	Public Health	6	6	1.7K
3	Engineering	1	1	89
4	Allergy	1	1	55
5	Biomolecular Engineering	1	1	47

Anna L. Goodman

Publications

12.7K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2021	1.2K
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study Cristina Menni, Kerstin Kläser, Anna May, The Lancet Infectious Diseases VaccinationVaccine Side-effectsPreventive MedicineSars-cov-2 InfectionCovid-19 Pandemic	2021	1.1K
Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody Alexander D. Douglas, Andrew R. Williams, Joseph J. Illingworth, Nature Communications VaccinationPathogenesisImmunologyMalariaMedicine	2013	924
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, The Lancet	2021	649
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial Christopher Butler, Richard Hobbs, Oghenekome Gbinigie, The Lancet Long CovidTreatment And PreventionCovid-19 PandemicAdverse OutcomesAntiviral Therapy	2022	391
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation Katie Ewer, Geraldine O’Hara, C.J. Duncan, Nature Communications	2013	289
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody Alexander D. Douglas, Andrew R. Williams, Joseph J. Illingworth, Nature Communications VaccinationPathogenesisImmunologyMalariaVaccine Design	2011	277
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial John Frater, Katie Ewer, Ane Ogbe, The Lancet HIV	2021	253
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin, The Lancet	2021	253

Page 1